FIELD: medicine; pharmaceuticals.
SUBSTANCE: present invention provides an orally disintegrating solid pharmaceutical dosage unit having a weight ranging from 50 to 1000 mg, wherein said dosage unit consists of: 5–100 wt % having a coating particles, containing 50–99 wt % core particle and 1–50 wt % coating, which covers from all sides core particle, wherein said coating consists of: 0.01–10 wt % generic activity controlling substance selected from oxytocin, carbetocin, atosiban and combinations thereof; 5–50 wt % a buffer agent; 15–80 wt % a branched glucan selected from dextran, glycogen, amylopectin and a combination thereof; 0.02–78 wt % other pharmaceutically acceptable ingredients; 1–95 wt % one or more pharmaceutically acceptable excipients; wherein said solid dosage unit includes at least 20 mcg of generic activity controlling substance and has a pH value of buffer within 3.5–5.7.
EFFECT: disclosed is an orally disintegrating solid pharmaceutical dosage unit containing a generic activity controlling substance.
14 cl, 12 tbl, 6 ex
Title | Year | Author | Number |
---|---|---|---|
ORALLY DISINTEGRATING SOLID PHARMACEUTICAL DOSAGE UNIT CONTAINING PARTUS CONTROL SUBSTANCE | 2015 |
|
RU2701199C2 |
STABILIZED COMPOSITION FOR ORAL ADMINISTRATION OF PEPTIDES | 1995 |
|
RU2140790C1 |
IMMEDIATE RELEASE AND PROLONGED RELEASE IBUPROFEN DOSING REGIMEN | 2007 |
|
RU2462242C2 |
OXYTOCIN ANALOGUES | 2009 |
|
RU2496788C2 |
PHARMACEUTICAL DOSED FORMULATION FOR DELIVERY THROUGH MUCOSA | 2003 |
|
RU2285520C2 |
PHARMACEUTICAL COMPOSITION | 2011 |
|
RU2604690C2 |
DESMOPRESSIN MEDICINAL FORMULATION DISPERSED IN MOUTH CAVITY | 2003 |
|
RU2292903C2 |
NOVEL FILM COATING | 2002 |
|
RU2323717C2 |
TABLET OF MELATONIN AND METHOD FOR PREPARING AND USING | 2008 |
|
RU2485949C2 |
FORM OF PHARMACEUTICAL DOSING PROVIDING THE PROLONGED RELEASE OF AN ACTIVE COMPONENT | 1993 |
|
RU2122413C1 |
Authors
Dates
2020-04-17—Published
2015-09-29—Filed